Cart
sales@molnova.com
Fosinopril sodium
CAS No. 88889-14-9
Fosinopril sodium( SQ 28,555 )
Catalog No. M16421 CAS No. 88889-14-9
Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 31 | In Stock |
|
| 10MG | 42 | In Stock |
|
| 25MG | 59 | In Stock |
|
| 50MG | 102 | In Stock |
|
| 100MG | 129 | In Stock |
|
| 200MG | 194 | In Stock |
|
| 500MG | 326 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFosinopril sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionFosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor.
-
DescriptionFosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.(In Vitro):Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2.Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2.Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM.(In Vivo):Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration.Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model.
-
In VitroFosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2.Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2.Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM.
-
In VivoFosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration.Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model. Animal Model:HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g) Dosage:4.67 mg/kg Administration:p.o.; 4 weeks Result:Against cardiac dysfunction and structural alteration and suppressed apoptosis.
-
SynonymsSQ 28,555
-
PathwayEndocrinology/Hormones
-
TargetRAAS
-
RecptorACE
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number88889-14-9
-
Formula Weight586.65
-
Molecular FormulaC30H45NO7P·Na
-
Purity>98% (HPLC)
-
SolubilityEthanol: 4 mg/mL (6.83 mM); Water: 117 mg/mL (199.78 mM)
-
SMILESCCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)[O-])C3CCCCC3.[Na+]
-
Chemical Namesodium;(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Sharma S, et al. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9.
molnova catalog
related products
-
ANGIOTENSIN IV TFA
ANGIOTENSIN IV TFA is a less effective agonist at the angiotensin AT1 receptor.
-
L162389
L162389 is an orally active and potent angiotensin II receptor antagonist with a balanced affinity for AT1 and AT2 receptor subtypes that stimulates the conversion of phosphatidylinositol.
-
Plantainoside D
Plantainoside D shows potent antioxidative effects as those of ascorbic acid it shows angiotensin-converting enzyme (ACE) inhibitory inhibitory activity in vitro with the IC(50) value of 2.17 mM it also shows inhibitory activity against PKCalpha with the IC50 value14.8microM.?
